Researchers called for dermatologists to recognize psoriasis-associated comorbidities, which can be managed more effectively with a multidisciplinary care team.

Collaborating with patients is essential for addressing sleep disturbances and mental health comorbidities, which are under-recognized in psoriasis.

ESK-001, a TYK2 inhibitor, showed promising efficacy and good tolerability in phase 2 for plaque psoriasis, prompting a phase 3 trial.

A recently developed treatment satisfaction tool called the DermSat-7 was valid and reliable for use in psoriasis management and clinical trials.

At the 2025 Winter Clinical Dermatology Conference, Ronald Vender, MD, discussed a psoriasis treatment goal algorithm for patients having inadequate response.

Once-daily ICP-488, a selective oral tyrosine kinase 2 (TYK2) inhibitor, significantly improved PASI scores in patients with moderate-to-severe plaque psoriasis compared with placebo at week 12, with a safety profile similar to placebo.

New findings from the phase 3 ICONIC-LEAD trial suggest that once-daily oral icotrokinra demonstrated significant, durable skin clearance and a safety profile similar to placebo in patients with plaque psoriasis.

Data from the Swiss Psoriasis Registry and the EuroGuiDerm guidelines highlight sex differences in psoriasis and the impact on health-related quality of life.

A new study suggests inadequate counseling and limited resources are among several barriers to educating patients on psoriasis’s link to cardiometabolic issues.

A presentation at the 2025 Winter Clinical meeting focused on pearls of wisdom for psoriasis treatment, including a breakdown of how obesity impacts therapies.

Psoriasis affects 7.5M+ U.S. adults, with new targeted treatments, diet links, and patient-centered care improving outcomes. Advances offer hope for better management.

Review highlights emerging psoriasis therapies, including IL-21, Snora73, gut microbiome, and natural treatments, offering new patient-centered options.